Global Registry SYMPLICITY demonstrated the safety of renal denervation system

The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal denervation safety and effectiveness in a real-world population with refractory hypertension. It plans to prospectively include a minimum of 5000 patients with refractory hypertension in 200 centers worldwide.In the 6-month analysis of the first 1000 patients included so far, showed adverse event rate of less than 1% and the absence of renal artery stenosis related to the procedure.The reduction in systolic blood pressure over the outpatientoffice was 11.9 mmHgand reduced pressure of 24 hour ambulatory monitoring was 7.9 mmHg.

Despite the record of GlobalSYMPLICITY registry is currently the largest on denervation of the renal artery and demonstrated safety and efficacy of the device overall discussions revolve around the negative results of randomized SIMPLICITY HTN 3.

5_michael_bohm
Michael Bohm
2014-03-31

Original title: The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension.

 

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....